Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jean-Pierre J Issa

Showing results (121-130 of 204) with videos related to

Pageof 21
Sort By:
Gut Microbes|June 11, 2024
Association between gut microbiota and CpG island methylator phenotype in colorectal cancerPyoung Hwa Park, Kelsey Keith, Gennaro Calendo, et al.
Oncogene|April 20, 2002
Inactivation of p57KIP2 by regional promoter hypermethylation and histone deacetylation in human tumorsTakefumi Kikuchi, Minoru Toyota, Fumio Itoh, et al.
Blood|July 23, 2005
JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemiaJaroslav Jelinek, Yasuhiro Oki, Vazganush Gharibyan, et al.
Cancer|January 20, 2007
Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemiaYasuhiro Oki, Hagop M Kantarjian, Vazganush Gharibyan, et al.
Cancer Prevention Research (Philadelphia, Pa.)|September 10, 2009
Concordant DNA methylation in synchronous colorectal carcinomasKazuo Konishi, Lanlan Shen, Jaroslav Jelinek, et al.
Human Molecular Genetics|July 23, 2003
Reactivation of the silenced and imprinted alleles of ARHI is associated with increased histone H3 acetylation and decreased histone H3 lysine 9 methylationSatoshi Fujii, Robert Z Luo, Jiuhong Yuan, et al.
Molecular Cancer Therapeutics|December 17, 2016
Repositioning FDA-Approved Drugs in Combination with Epigenetic Drugs to Reprogram Colon Cancer EpigenomeNoël J-M Raynal, Elodie M Da Costa, Justin T Lee, et al.
Clinical Epigenetics|July 24, 2019
Genomic and epigenomic predictors of response to guadecitabine in relapsed/refractory acute myelogenous leukemiaWoonbok Chung, Andrew D Kelly, Patricia Kropf, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 16, 2007
Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancerLanlan Shen, Minoru Toyota, Yutaka Kondo, et al.
Blood|November 8, 2003
Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignanciesJean-Pierre J Issa, Guillermo Garcia-Manero, Francis J Giles, et al.
Pageof 21

Showing results (121-130 of 204) with videos related to

Sort By:
Pageof 21
Gut Microbes|June 11, 2024
Association between gut microbiota and CpG island methylator phenotype in colorectal cancerPyoung Hwa Park, Kelsey Keith, Gennaro Calendo, et al.
Oncogene|April 20, 2002
Inactivation of p57KIP2 by regional promoter hypermethylation and histone deacetylation in human tumorsTakefumi Kikuchi, Minoru Toyota, Fumio Itoh, et al.
Blood|July 23, 2005
JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemiaJaroslav Jelinek, Yasuhiro Oki, Vazganush Gharibyan, et al.
Cancer|January 20, 2007
Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemiaYasuhiro Oki, Hagop M Kantarjian, Vazganush Gharibyan, et al.
Cancer Prevention Research (Philadelphia, Pa.)|September 10, 2009
Concordant DNA methylation in synchronous colorectal carcinomasKazuo Konishi, Lanlan Shen, Jaroslav Jelinek, et al.
Human Molecular Genetics|July 23, 2003
Reactivation of the silenced and imprinted alleles of ARHI is associated with increased histone H3 acetylation and decreased histone H3 lysine 9 methylationSatoshi Fujii, Robert Z Luo, Jiuhong Yuan, et al.
Molecular Cancer Therapeutics|December 17, 2016
Repositioning FDA-Approved Drugs in Combination with Epigenetic Drugs to Reprogram Colon Cancer EpigenomeNoël J-M Raynal, Elodie M Da Costa, Justin T Lee, et al.
Clinical Epigenetics|July 24, 2019
Genomic and epigenomic predictors of response to guadecitabine in relapsed/refractory acute myelogenous leukemiaWoonbok Chung, Andrew D Kelly, Patricia Kropf, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 16, 2007
Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancerLanlan Shen, Minoru Toyota, Yutaka Kondo, et al.
Blood|November 8, 2003
Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignanciesJean-Pierre J Issa, Guillermo Garcia-Manero, Francis J Giles, et al.
Pageof 21